Season 3 - Ep.2: The why and how of MRAs in Heart Failure - Managing electrical storm

Oct 10, 2024

Guest

Carlos Aguiar

Guest

Sana Al-Khatib

Guest

Rudolf de Boer

In this engaging discussion, guests Carlos Aguiar, a leading cardiology expert, Sana Al-Khatib from Duke University, and Rudolf de Boer from Erasmus University dive into the intricacies of heart failure treatment. They clarify which mineralocorticoid receptor antagonists (MRAs) suit different heart failure patients. Sana tackles the complex management of electrical storms, while Rudolf sheds light on the use of aldosterone antagonists. The group also debunks myths, like garlic's role in heart health, ensuring listeners stay well-informed on vital cardiovascular topics.

Ask episode

Chapters

Transcript

Episode notes

Intro

00:00 • 3min

Understanding Cardiovascular Risks: Recovery Delays and Holiday Heart Syndrome

02:56 • 3min

Aldosterone Antagonists in Heart Failure Treatment

06:05 • 6min

Understanding Electrical Storms in Cardiology

12:13 • 6min

Exploring the Cardiovascular Benefits of Garlic

18:04 • 5min

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies
The why and how of MRAs in Heart Failure
Managing electrical storm
Mythbusters: garlic protects from the heart disease

Host: Perry Elliott

Guests: Carlos Aguiar, Sana Al-Khatib, Rudolf de Boer

Want to watch that episode? Go to: https://esc365.escardio.org/event/1792

Disclaimer

ESC TV Today is supported by Bristol Myers Squibb.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Sana Al-Khatib and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo.

Rudolf de Boer has declared to have potential conflicts of interest to report: direct research funding from European Research Council (ERC), Netherlands Heart Foundation, Fondation leDucq, Netherlands Organization for Scientific Research. Research funding to department or institution: AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, NovoNordisk. Direct fees from Abbott, AstraZeneca, Cardior Pharmaceuticals GmbH, NovoNordisk, Roche Diagnostics. Fees to department or institution: NovoNordisk.

Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.